🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Hepatoblastoma- treatment outcomes and prognostic factors ⁦Tata Memorial Hospital⁩ Congrats for a nice paper in this month’s PBC. #ShyamS ⁦Badira Cheriyalinkal Parambil⁩ ⁦#SajidQureshi #NehalKhanna #SiddharthLaskar⁩ #GirishChinnaswamy #MayaPrasad and team onlinelibrary.wiley.com/doi/10.1002/pb…

Two days of interactive academic sessions at Pediatric solid tumour workshop Tata Memorial Hospital Mumbai. More than 200 attendees and 30 faculty ( national and international) PHO INDIA INPHOG Vasudeva Bhat K Kalasekhar Vijayasekharan

In this study, the addition of blinatumomab to standard chemotherapy improved disease-free and overall survival among infants with KMT2A-rearranged ALL, with minimal additional toxic effects. nej.md/3HfuHwt

Check out our latest publication in AmericanJournalofHematology: onlinelibrary.wiley.com/doi/10.1002/aj… We assessed MRD by high-sensitivity NGS-based assay for IG/TCR vs. standard of care PCR for BCR::ABL1 in patients with newly diagnosed Ph+ ALL. #ALLsm Nicholas Short MD Hagop Kantarjian,MD MD Anderson Cancer Center

Granulocyte may be the answer for treating MDRO sepsis in children with cancer. Glad to be part of this study from Tata Memorial Hospital , Mumbai. Gaurav Narula MD Chetan Dhamne Badira Cheriyalinkal Parambil Kalasekhar Vijayasekharan Venky Nidhi Dhariwal Shyam doi.org/10.1002/pbc.30…

Tailored strategies and targetted immunotherapies - need of the hour in LMICs for managing Pediatric relapse B ALL. Happy to be part of this study from Tata Memorial Hospital Gaurav Narula MD Shyam Venky Subramaniam Ramanathan Deepak Bansal Nidhi Dhariwal link.springer.com/article/10.100…

Acute Promyelocytic Leukemia: a malignancy with excellent outcomes, provided initial coagulopathy is managed vigilantly Had a wonderful panel discussion on Pediatric #APL moderated by DrShyam Srinivasan(TMH) and chaired by legendary Prof Banavali , at #Medica Cancer Conclave

Glad to share our work on Methotrexate induced neurotoxicity in pediatric ALL doi.org/10.1080/104281… Long story short, safe re-challenge is possible! @NirmalyaRoyMoulik Swaminathan K Shyam Gaurav Narula MD CHETAN DHAMNE Kalasekhar Vijayasekharan Vasudeva Bhat K Badira Cheriyalinkal Parambil

Precision medicine for children with cancer: 📚 Essential Reading: Dive into Ian F Tannock's Latest Comment! 🔍 #MustRead The Lancet Common Sense Oncology ASCO ESMO - Eur. Oncology OncoAlert doi.org/10.1016/S1470-…

📢Exon 17 KIT mutation associated with⬆️relapse risk &⬇️overall survival in childhood RUNX1::RUNX1T1 AML. 🌟A high KIT VAF (>33%) correlated with poor survival. ❓Alternative strategy. doi.org/10.1002/pbc.30… Chetan Dhamne Gaurav Narula MD Nikhil Patkar Gaurav Chatterjee Tata Memorial Hospital

Another PBC must-read: KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1 #PedsHemeOnc #PHODocs #PHOAPPs ow.ly/4mqR50QkNmX

India’s first CAR-T cell therapy is developed through collaboration between the Indian Institute of Technology, Bombay and Tata Memorial Hospital in association with industry partner ImmunoACT. So, we have two of India’s pioneering research institutes in their respective fields,

Our Findings on risk factors for MTX neurotoxicity in Pediatric Leukemia/Lymphoma published British Journal of Haematology in a large cohort of 622 patients onlinelibrary.wiley.com/doi/abs/10.111… older children with Cns leukemia and developing tumor lysis may be at higher risk, led by Thirumala Rupakumar Ajay Menon🦒🦒🦒

🚨 New study alert! Shyam Gaurav Narula MD Chetan Dhamne Using fixed low-dose nivolumab (40mg D1 & D15; ~1.2mg/kg) + bendamustine, we achieved 88% CR after 2 cycles in high-risk pediatric rrHL. Full article: doi.org/10.1111/bjh.20… #PedsOnc #HodgkinLymphoma #Immunotherapy